Diagnostics of progression of liver fibrosis in patients with non-alcoholic steatohepatitis combined with obesity and chronic calculous cholecystitis.

Автор(и)

DOI:

https://doi.org/10.26641/2307-0404.2020.1.200403

Ключові слова:

nonalcoholic steatohepatitis, obesity, fibrosis, histological diagnostics

Анотація

The aim of the work is to investigate the diagnostic value of laboratory blood biomarkers – alanine aminotransferase, aspartate aminotransferase, oxyproline and prothrombin time in comparison with morphological indicators for diagnosis of the degree of liver fibrosis in patients with comorbid course of non-alcoholic steatohepatitis (NASH) combined with obesity and chronic calculous cholecystitis. The data of 22 patients with NASH combined with obesity and chronic calculous cholecystitis was analyzed by laboratory and morphological indicators. There were 6 (27.2%) men and 16 (72.8%) women among the patients. Liver biopsy was performed intra-operatively on performing surgical treatment of calculus cholecystitis. METAVIR and Е. Brunt criteria were used in the histological diagnosis of NASH, as well as for determination of the stage of liver fibrosis (LF). Hepatic tissue fibrogenesis was assessed by serum values of total (OPT), free (OPF) and protein-bound (OPB) oxyproline, activity of indirect fibrosis markers – alanine ami­notransferase (ALT), aspartate aminotransferase (AST), AST/ALT ratio and prothrombin time (РТТ). As a mathematical tool for modeling, stepwise discriminant analysis was used. Fibrosis of the first stage (F1) was observed in 5 (22.7%) patients, the second stage of fibrosis (F2) – in 7 (31.8%), F3 stage of fibrosis - in 10 (45.5%) patients. Analysis of the morphological study of liver biopsy samples in examined patients with NASH indicates that established histological changes combine the signs of fatty and protein degeneration of hepatocytes, inflammation and necrosis in the lobules. Among the indicators included in the mathematical model the highest diagnostic significance can be attributed to the AST / ALT ratio (F = 9.03; p = 0.003) and the level of OPF (F = 5.67; p = 0.016), whereas OPB level has the lowest value (F = 2.94; p = 0.086). Evaluation of the accuracy of the method for determining of the LF phase based on the proposed algorithm showed that the frequency of correct detecting of F1 and F2 stages of LF was 100%, for the F3 stage - 90% (1 case attributed to the F2 stage). In general, the accuracy of the method was 95.5% (95% CI 86.8-100%), sensitivity – 90.0% (95% CI 71.4-100%), specificity – 100% (95% CI 92,5 – 100%), validity - 90.0%. Evaluation of the stage of LF in patients with NASH combined with obesity and chronic calculous cholecystitis, which was determined using discriminant functions calculated from laboratory data (OPT, OPF, OPB, ALT, AST / ALT ratio and PTT), is very much in line with the corresponding results of histopathological studies of liver biopsy samples.

Біографія автора

A. Yu. Filippova

SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine»
Department of Internal Medicine 2 and phthisiology
V. Vernadsky str., 9, Dnipro, 49044, Ukraine 

Посилання

Antomonov MYu. [Mathematical processing and analysis of biomedical data]. 2nd ed. Kyiv: MITS «Medinform»; 2018. p. 576. Ukrainian.

Kamyshnikov VS. [Clinical and laboratory diag­nosis of liver diseases]. 3nd ed. Moskva: MEDpress-inform; 2019. p. 96. Russian.

Stepanov YuM., Filippova OYu. [Morphological basis for the assessment of steatosis, steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease in combination with obesity and pathology of the biliary tract]. Hastroenterolohiia.2017;51(3):196-204. Ukrainian. doi: https://doi.org/10.22141/2308-2097.51.3.2017.112636

Filippova OYu. [Changes in direct markers of liver fibrosis in patients with steatohepatitis non-alcoholic and alcoholic origin on the background of obesity and pathology of the biliary tract]. Zaporizh. med. zhurnal. 2017;2(101):168-71. Ukrainian. doi: https://doi.org/10.14739/2310-1210

Filippova OYu, Hubar IO. [Criteria for the fore­casting of the disease of nonalcoholic steatohepatitis in patients with obesity and pathology of the biliary tract]. Svit medytsyny ta biolohii. 2017;4(62):99-103. Ukrainian. doi: https://doi.org/10.26724/2079-8334-2017-4-62-99-103

Filippova OYu, Hubar IO, Rudakova VV. [Pre­diction of the flow and progression of nonalcoholic fatty liver disease in patients with obesity and pathology of the biliary tract with the help of mathematical modeling]. Medicni perspektivi. 2017:22(4):74-80. Ukrainian. doi: https://doi.org/10.26641/2307-0404.2017.4.117674.

Ahmed A, Wong RJ, Harrison SA. Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Out­comes. Clin Gastroenterol Hepatol. 2015;13(12):2062-70. doi: https://doi.org/10.1016/j.cgh.2015.07.029

Bedossa P, Poynard T. An algorhythm for the gra­ding of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24(2):289-93. doi: https://doi.org/10.1002/hep.510240201

Gu Z, Li D, He H. Body mass index, waist cir­cumference, and waist-to-height ratio for prediction of multiple metabolic risk factors in Chinese elderly popu­lation. Sci Rep. 2018;8(1):385. doi: https://doi.org/10.1038/s41598-017-18854-1

Brunt EM, Neuschwander-Tetri BA, Oliver D. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. Hum. Pathol. 2004;35(9):1070-1082. doi: https://doi.org/10.1016/j.humpath.2004.04.017

Carr RM, Oranu A, Khungar V. Nonalcoholic Fatty Liver Disease: Pathophysiology and Management. Gastroenterol Clin North Am. 2016;45(4):639-52. doi: https://doi.org/10.1016/j.gtc.2016.07.003

Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Practice & Research Clinical Gastroenterology. 2014;28(4):637-53. doi: https://doi.org/10.1016/j.bpg.2014.07.008

El-Kader SMA. Non-alcoholic fatty liver disease: The diagnosis and management. World Journal of Hepatology. 2015;7(6):846-58. doi: https://doi.org/10.4254/wjh.v7.i6.846

Filippova A. Non-alcoholic steatohepatitis in patients with obesity: interconnection between body mass, changes of lipid metabolism and concomitant pathology of biliary tract. EUREKA: Health Sciences. 2016;4:3-11. doi: https://doi.org/10.21303/2504-5679.2016.00115

Younossi Z, Anstee QM, Marietti M. Global bur­den of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11-20. doi: https://doi.org/10.1038/nrgastro.2017.109

Zhang CY, Yuan WG, He P. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. World J Gastroenterol. 2016;22(48):10512-22. doi: https://doi.org/10.3748/wjg.v22.i48.10512

##submission.downloads##

Опубліковано

2020-04-09

Як цитувати

1.
Filippova AY. Diagnostics of progression of liver fibrosis in patients with non-alcoholic steatohepatitis combined with obesity and chronic calculous cholecystitis. Med. perspekt. [інтернет]. 09, Квітень 2020 [цит. за 26, Листопад 2024];25(1):65-73. доступний у: https://journals.uran.ua/index.php/2307-0404/article/view/200403

Номер

Розділ

КЛІНІЧНА МЕДИЦИНА